Compare Roundhill Magnificent Seven ETF (MAGS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Zoetis Inc — how do they compare? Roundhill Magnificent Seven ETF trades at $67.15, while Zoetis Inc trades at $74.89 (market cap $31.95B). The key difference: Zoetis Inc pays a 2.78% dividend while Roundhill Magnificent Seven ETF pays none, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| MAGS | ZTS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.94 | $156.76 |
52-Week Low | $55.39 | $71.91 |
Market Cap | — | $31.95B |
Enterprise Value | — | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS, the Roundhill Magnificent Seven ETF, trades at $66.93, showing minimal daily movement with a neutral technical signal. It holds an equal-weight basket of seven mega-cap tech stocks, benefiting from AI-driven market trends but facing concentration risks. Recent news highlights AI spending shifts and broadening market gains beyond chipmakers.
The ETF's outlook hinges on AI adoption and hyperscaler performance, with potential from compressed valuations, but risks include overconcentration and high expectations. Institutional interest remains strong, though analyst views are mixed amid sector rotation.
Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.
The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
